

S1 Table. Characteristics of studies reporting on proportion of asymptomatic SARS-CoV-2 infections (Q1) and the secondary attack rate of SARS-CoV-2 infections by symptom status (Q2.1)

Study	Location <sup>b</sup>	Total SARS-CoV-2, n	People with asymptomatic SARS-CoV-2 infection			Follow-up method <sup>a</sup>
			n	Sex	Age	
Contact and outbreak investigations						
Arons MM, 2020	United States of America, Seattle	47	3	NR	NR	2
Bi Q, 2020	China, Shenzhen	87	17	NR	NR	2, 3, 4
Böhmer MM, 2020	Germany, Bavaria	16	1	NR	NR	1, 2
Brandstetter S, 2020	Germany, Regensburg	36	2	NR	NR	2, 3
Cheng HY, 2020	Taiwan	22	4	NR	NR	1
Corcorran MA, 2020	United States of America, Washington	8	3	NR	NR	2, 4
Danis K, 2020	France	12	1	NR	NR	1, 2, 3
Dora AV, 2020	United States of America, Los Angeles	16	6	0 F, 6 M	75 IQR 72-75	4
Graham N, 2020	United Kingdom, London	126	46	NR	NR	2
Grijalva CG, 2020	United States of America, Tennessee and Wisconsin	102	34	NR	NR	2
Harada S, 2020 [Healthcare workers]	Japan, Tokyo	49	25	NR	NR	2, 3
Harada S, 2020 [Patients]	Japan, Tokyo	24	8	NR	NR	2, 3
Hijnen D, 2020	Germany, Munich	11	1	0 F, 1 M	49	1, 2
Hurst JH, 2020	United States of America, North Carolina	293	87	NR	NR	2
Jones A, 2021	United States of America, Vermont	87	24	NR	NR	1, 2
Kasper MR, 2020	United States of America	1,271	572	NR	NR	2, 3

Study	Location <sup>b</sup>	Total SARS-CoV-2, n	People with asymptomatic SARS-CoV-2 infection			Follow-up method <sup>a</sup>
			n	Sex	Age	
Kennelly SP, 2020 [Nursing home residents]	Ireland, NR	710	193	NR	NR	2
Kennelly SP, 2020 [Nursing home staff]	Ireland, NR	395	97	NR	NR	2
Kittang BR, 2020	Norway, Bergen	40	0	NR	NR	1, 2
Ladhani SN, 2020 [Healthcare workers]	United Kingdom, London	53	26	NR	NR	2, 3
Ladhani SN, 2020 [Residents]	United Kingdom, London	105	46	NR	NR	2, 3
Lee JY, 2020	South Korea, Daegu	694	80	NR	NR	2
Luo L, 2020	China, Guangzhou	127	8	NR	NR	1, 3
Njuguna H, 2020	United States of America, Louisiana	71	29	NR	NR	1, 2
Park JH, 2020	South Korea	28	4	NR	NR	1, 2
Park SY, 2020	South Korea, Seoul	95	4	NR	NR	2, 3
Patel MC, 2020	United States of America, Illinois	35	13	NR	NR	2, 3
Pavli A, 2020	Greece	46	7	NR	NR	1, 2
Pham QT, 2020	Vietnam	208	89	NR	31 IQR 23-45	2
Pirnay JP, 2020	Belgium	9	4	0 F, 4 M	34.5 IQR 24-44.5	1
Plucinski, 2020	Japan	66	14	NR	NR	2
Redditt V, 2020	Canada, Toronto	24	3	NR	NR	2, 3
Romao VC, 2020	Portugal, Lisbon	14	0	NR	NR	4
Schwierzeck V, 2020	Germany, Muenster	11	2	NR	NR	2
Shi Q, 2020	China, Wanzhou District	183	60	NR	NR	4
Taylor J, 2020 [Healthcare personnel]	United States of America, Minnesota	99	9	NR	NR	2, 3

Study	Location <sup>b</sup>	Total SARS-CoV-2, n	People with asymptomatic SARS-CoV-2 infection			Follow-up method <sup>a</sup>
			n	Sex	Age	
Taylor J, 2020 [Residents]	United States of America, Minnesota	127	7	NR	NR	2, 3
Tian S, 2021	China, Shandong	24	7	NR	NR	2, 4
van den Besselaar JH, 2021 [Healthcare workers]	Netherlands, South Holland	54	1	NR	NR	2, 3
van den Besselaar JH, 2021 [Residents]	Netherlands, South Holland	113	7	NR	NR	2, 3
Wu J, 2020	China, Zhuhai	48	5	NR	NR	1, 2, 3
Yang N, 2020	China, Xiaoshan	10	2	1 F, 1 M	26	1, 2
Yau K, 2020	Canada, Toronto	20	7	NR	NR	2, 3
Yousaf AR, 2020	United States of America, Utah	47	0	NR	NR	2, 3
Zhang W, 2020	China, Guangzhou	12	4	NR	NR	1, 2, 4
<i>Screening in community, institutional and occupational settings</i>						
AbdulRahman A, 2020	Bahrain	6	3	0 F, 3 M	25	2, 4
Adhikari EH, 2020	United States of America, Texas	252	98	98 F, 0 M	NR	2, 3
Almazeedi S, 2020	Kuwait	1,096	473	NR	NR	4
Al-Qahtani M, 2020	Bahrain	188	116	NR	NR	2, 3, 4
Alshahrani MS, 2020	Saudi Arabia, Alkhobar	18	12	NR	NR	4
Andrikopoulou M, 2020	United States of America, New York	158	46	46 F, 0 M	NR	2
Aslam A, 2020	United States of America, New York	65	38	NR	NR	2, 3

Study	Location <sup>b</sup>	Total SARS-CoV-2, n	People with asymptomatic SARS-CoV-2 infection			Follow-up method <sup>a</sup>
			n	Sex	Age	
Balestrini S, 2020	United Kingdom, London	17	11	NR	NR	4
Bender WR, 2020	United States of America, Philadelphia	8	6	6 F, 0 M	NR	2, 3
Berghoff AS, 2020	Austria, Vienna	4	2	NR	53 IQR 43-63	1, 2, 4
Bogani G, 2020	Italy, Lombardy	19	10	10 F, 0 M	NR	4
Cao S, 2020	China, Wuhan	300	300	168 F, 132 M	NR	1, 4
Cariani L, 2020	Italy, Milan	182	32	NR	NR	2, 4
Chamie G, 2020	United States of America, San Francisco	81	23	NR	NR	2, 3
Chang L, 2020	China, Wuhan	4	2	0 F, 2 M	45 IQR 37-53	2, 4
Edelstein M, 2020	United Kingdom, London	20	4	NR	NR	3, 4
Eythorsson E, 2020	Iceland	178	25	NR	NR	2, 3
Ferreira VH, 2021	Canada, Toronto	9	5	5 F, 0 M	33 IQR 4.75	2, 3
Ghinai I, 2020	United States of America, Chicago	406	293	NR	NR	2, 3
Green R, 2021	United Kingdom, Liverpool	22	22	15 F, 7 M	80 IQR 19-106	2, 3
Han X, 2020	China, Wuhan	17	17	8 F, 9 M	30 IQR 27-30	2
Hcini N, 2020	French Guyana, West French Guiana territory	137	87	87 F, 0 M	NR	2, 3
Hoehl S, 2020	Germany, Gernersheim	2	1	0 F, 1 M	58	2

Study	Location <sup>b</sup>	Total SARS-CoV-2, n	People with asymptomatic SARS-CoV-2 infection			Follow-up method <sup>a</sup>
			n	Sex	Age	
Hogan CA, 2021	United States of America, California	38	20	13 F, 7 M	41 IQR 32.5-47	2, 3
Kirshblum SC, 2020	United States of America, New Jersey	12	2	NR	NR	2, 3
Kutsuna S, 2020	Japan, Tokyo	11	3	1 F, 2 M	NR	2, 4
Lavezzo E, 2020	Italy, Veneto	73	29	NR	NR	2
Letizia AG, 2020	United States of America, South Carolina	51	46	NR	NR	1, 2
Lombardi A, 2020	Italy, Lombardy	139	17	NR	NR	1, 2, 4
London V, 2020	United States of America, New York City	68	22	22 F, 0 M	30.5 IQR 24.5-34.8	2, 3
Mahajan NN, 2020	India, Mumbai	467	58	NR	NR	4
Malagón-Rojas J, 2020	Colombia, Bogota	35	11	NR	NR	2, 3
Marossy A, 2020	United Kingdom, London	67	46	NR	NR	2, 4
Meyers KJ, 2021	United States of America, Indianapolis	86	67	NR	NR	2, 3
Migisha R, 2020	Uganda	54	20	NR	NR	2, 3
Pizarro-Sánchez MS, 2021	Spain, Madrid	38	5	2 F, 3 M	NR	2, 3
Rauch JN, 2021	United States of America, California	6	2	NR	NR	2, 3
Rivett L, 2020	United Kingdom, Cambridge	30	5	NR	NR	2
Shi SM, 2020	United States of America, Boston	146	21	NR	NR	2, 3
Smith E, 2020	United Kingdom, Norfolk	103	42	NR	NR	2, 3
Starling A, 2020	United Kingdom, Essex	31	29	NR	NR	2, 3

Study	Location <sup>b</sup>	Total SARS-CoV-2, n	People with asymptomatic SARS-CoV-2 infection			Follow-up method <sup>a</sup>
			n	Sex	Age	
Stock AD, 2020	United States of America, New York City	19	6	NR	NR	1, 2
Tanacan A, 2020	Turkey, Ankara	3	0	NR	NR	4
Tan-Loh J, 2021	Malaysia, Teluk Intan	46	6	NR	NR	2, 3, 4
Theuring S, 2021 [Household members]	Germany, Berlin	14	0	NR	NR	2, 3
Theuring S, 2021 [School students and staff]	Germany, Berlin	10	2	NR	NR	2, 3
Treibel TA, 2020	United Kingdom, London	44	12	NR	NR	2, 3
van Buul LW, 2020 [Healthcare workers]	Netherlands, NR	9	0	NR	NR	2, 3
van Buul LW, 2020 [Nursing home residents]	Netherlands, NR	16	3	NR	NR	2, 3
Varnell C, 2021	United States of America	10	5	NR	NR	2
Viñuela MC, 2020	Spain, Madrid	8	8	8 F, 0 M	32	4
Wadhwa A, 2020	United States of America, Chicago	17	6	NR	NR	2
White EM, 2020	United States of America	5,403	2,194	NR	NR	2, 3
Wi YM, 2020	South Korea, Gyeongsangnam-do province	111	7	NR	NR	4
Wong J, 2020	Brunei	138	16	NR	NR	2, 4

SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; NR, not reported; F, female; M, male; IQR, interquartile range.

<sup>a</sup>Follow-up recorded according to study protocol (1: 14 days after last possible exposure; 2: 7 days after diagnosis; 3:>7 days after diagnosis; 4: until negative RT-PCR result).

<sup>b</sup>Location is reported as described in the study.